Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study (vol 11, e0164455, 2016)

被引：0

作者：

Troya, Jesus ^{[1
]}

Ryan, Pablo ^{[1
]}

Ribera, Esteban ^{[1
]}

Podzamczer, Daniel ^{[1
]}

Hontanon, Victor ^{[1
]}

Alberto Terron, Jose ^{[1
]}

Boix, Vicente ^{[1
]}

Moreno, Santiago ^{[1
]}

Barrufet, Pilar ^{[1
]}

Castano, Manuel ^{[1
]}

Carrero, Ana ^{[1
]}

Jose Galindo, Maria ^{[1
]}

Suarez-Lozano, Ignacio ^{[1
]}

Knobel, Hernando ^{[1
]}

Raffo, Miguel ^{[1
]}

Solis, Javier ^{[1
]}

Yllescas, Maria ^{[1
]}

Esteban, Herminia ^{[1
]}

Gonzalez-Garcia, Juan ^{[1
]}

Berenguer, Juan ^{[1
]}

Imaz, Arkaitz ^{[1
]}

机构：

[1] Hosp Univ Gregorio Maranon, Madrid, Spain

来源：

PLOS ONE | 2017年 / 12卷 / 02期

关键词：

D O I：

10.1371/journal.pone.0172184

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页数：1

共 25 条

[1] Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Troya, Jesus
Ryan, Pablo
Ribera, Esteban
Podzamczer, Daniel
Hontanon, Victor
Alberto Terron, Jose
Boix, Vicente
Moreno, Santiago
Barrufee, Pilar
Castano, Manuel
Carrero, Ana
Jose Galindo, Maria
Suarez-Lozano, Ignacio
Knobel, Hernando
Raffo, Miguel
Solis, Javier
Yllescas, Maria
Esteban, Herminia
Gonzalez-Garcia, Juan
Berenguer, Juan
Imaz, Arkaitz
PLOS ONE, 2016, 11 (10):
[2] Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
Troya, Jesus
Montejano, Rocio
Ryan, Pablo
Gomez, Cristina
Matarranz, Mariano
Cabello, Alfonso
Vera, Francisco
Antonia Sepulveda, Maria
Santos, Ignacio
Samperiz, Gloria
Bachiller, Pablo
Boix, Vicente
Barrufet, Pilar
Cervero, Miguel
Sanz, Jose
Solis, Javier
Yllescas, Maria
Valencia, Eulalia
PLOS ONE, 2018, 13 (06):
[3] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in patients with suppressed HIV-1
Chounta, V.
Snedecor, S.
Van de Velde, N.
HIV MEDICINE, 2020, 21 : 28 - 29
[4] Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: A 48-week pilot study
Elion, Richard
Cohen, Calvin
deJesus, Edwin
Redfield, Robert
Gathe, Joseph
Hsu, Ricky
Yau, Linda
Ross, Lisa
Ha, Belinda
Lanier, E. Randall
Scott, Trevor
HIV CLINICAL TRIALS, 2006, 7 (06): : 324 - 333
[5] A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naive HIV-1-Infected Patients: 48-Week Results of the SHIELD Trial
Young, Benjamin
Vanig, Thanes
DeJesus, Edwin
Hawkins, Trevor
St Clair, Marty
Yau, Linda
Ha, Belinda
HIV CLINICAL TRIALS, 2010, 11 (05): : 260 - 269
[6] Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Walmsley, Sharon
Baumgarten, Axel
Berenguer, Juan
Felizarta, Franco
Florence, Eric
Marie-Aude Khuong-Josses
Kilby, J. Michael
Lutz, Thomas
Podzamczer, Daniel
Portilla, Joaquin
Roth, Norman
Wong, Deborah
Granier, Catherine
Wynne, Brian
Pappa, Keith
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 70 (05) : 515 - 519
[7] Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial (vol 70, pg 515, 2015)
Walmsley, S.
Baumgarten, A.
Berenguer, J.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (01) : E33 - E33
[8] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
Campo, R.
DeJesus, E.
Bredeek, U. F.
Henry, K.
Khanlou, H.
Logue, K.
Brinson, C.
Benson, P.
Dau, L.
Wang, H.
White, K.
Flaherty, J.
Fralich, T.
Guyer, B.
Piontkowsky, D.
CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) : 1637 - 1645
[9] Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study
Elion, Richard
deJesus, Edwin
Sension, Michael
Berger, Daniel
Towner, William
Richmond, Gary
Clair, Marty St.
Yau, Linda
Ha, Belinda
HIV CLINICAL TRIALS, 2008, 9 (03): : 152 - 163
[10] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen (vol 56, pg 1637, 2013)
Campo, R.
DeJesus, E.
Bredeek, U. F.
Henry, K.
Khanlou, H.
Logue, K.
CLINICAL INFECTIOUS DISEASES, 2013, 57 (05)

← 1 2 3 →